Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel With or Without PF-3512676 in Advanced Breast Cancer
NCT00471159Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Aug 2007
01
Overview
Phase 2, randomised, open-label trial of agatolimod in breast cancer, sponsored by Pfizer. Primary endpoints: Progression-Free Survival and Tumor assessment at 6 weeks. Planned start Aug 2007; status: withdrawn.
02
Drugs
agatolimod
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00471159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00471159.